KRAS mutation (KRAS*)—the key driver mutation in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCL)—also plays a secondary role in colorectal carcinoma (CRC) progression [114]. This evidence concerns the gene KRAS and colorectal carcinoma.